Modeling of Cardiotoxicity with Human PSCs
An important goal during the process of drug development is to assess whether drug candidates have toxic effects that would prevent their clinical use.33 Cardiotoxicity is a particular concern. Increased risk of ventricular arrhythmia has been involved in 28% of drug withdrawals from the U.S. market, showing that drug candidates that were apparently safe in preclinical models could prove to be unsafe when used by patients